Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
Chris Tachibana, PhD, MS
Chris Tachibana is a Staff Writer for Penn LDI. She is also Senior Managing Editor of the journal Health Services Research, and a scientific editor for Kaiser Permanente Washington Health Research Institute. Before moving to a career in scientific writing and editing, she was a research scientist and undergraduate instructor at the University of Washington and Penn State University. She also taught at Salt Lake Community College. She holds a BA from Whitman College, an MS from Cornell University, and a PhD from the University of Oregon.
Related Content
Why You May Have Fewer Health Insurance Choices Than Your Neighbor
Insurers Avoid Counties With Small Populations and Poor Health but a New LDI Study Finds Limited Evidence of Anticompetitive Behavior
Participation in Medicare Advantage Risk-Based Provider Payments Shows Little Impact on Care Delivery
Moving from Fee-for-Service to Risk-Based Contracts Hasn’t Dramatically Changed Patient Care, Raising Questions About How to Make These Models More Effective
Black and Hispanic Children Have Higher Death Rates Than White Children After In-Hospital CPR
Equitably Improving Care for Hospitalized Kids Who Experience Cardiac Arrest Requires Hospital-Level Changes, LDI Fellows Say
Less Postacute Care for Medicare Advantage Beneficiaries Does Not Mean Worse Health
Research Brief: Shorter Stays in Skilled Nursing Facilities and Less Home Health Didn’t Lead to Worse Outcomes, Pointing to Opportunities for Traditional Medicare
Hospitals Rarely Use Z Codes to Document Patients’ Social Risks
Billing Codes That Flag Food, Job, or Housing Insecurity in Medical Records are Underused for the Sickest Medicare Patients